Table 1.
Day | 0 | 1 | 2 | 2 | 3 | 3 | 8 | 8 | 9 | 10 | 11 | 11 | 12 | 27 | 33 | 39 |
Time | 10:00 | 01:10 | 10:20 | 14:10 | 08:25 | 20:00 | 12:50 | 21:20 | 15:50 | 04:40 | 04:10 | 16:30 | 03:40 | 12:40 | 17:10 | 10:00 |
Intervention | COVID-19 PCR positive | 07:00 steroid started | Day 4 15:00 tocilizumab given |
15:00 TTE PFO and RTLIAS anticoagulated |
13:00 tracheal intubation |
13:00 TOE no RTLIAS |
Tracheal extubation |
Home | ||||||||
Lymphocytes, ×109/L | 0.67 | 0.92 | 0.79 | 0.53 | 0.65 | 0.73 | 2.45 | |||||||||
CRP, mg/L | 76 | 70 | 39 | 7 | 17 | 27 | ||||||||||
Ferritin, µg/L | 1847 | 2925 | 1979 | 785 | 892 | |||||||||||
D-dimer, mg/L | 0.54 | 0.55 | 0.74 | 9.65 | 1.95 | 1.12 | ||||||||||
LDH, U/L | 791 | 901 | 1167 | 726 | ||||||||||||
SpO2, % | 94 | 91 | 93 | 90 | 92 | 91 | 84 | 94 | 91 | 98 | 98 | 92 | 95 | 92 | 95 | 95 |
RR, breaths/min | 24 | 29 | 29 | 30 | 36 | 35 | 29 | 28 | 24 | 32 | 30 | 30 | 30 | 32 | 22 | 21 |
Position | Sitting | Sitting | Sitting | Sitting | Sitting | Prone | Sitting | Prone | Supine | Prone | Supine | Supine | Prone | Sitting | Sitting | |
Respiratory
support |
NC | FM | NRB FM | NRB FM | HFNC | HFNC | Helmet BiPAP |
ETT VC+ |
ETT VC AC |
ETT VC AC |
ETT VC AC |
ETT VC AC |
HFNC | NC | ||
FiO2 | 0.21 | 0.35 | 0.7 | 1.0 | 1.0 | 0.6 | 0.5 | 0.5 | 0.4 | 0.5 | 0.21 | |||||
Flow, L/min | 1 | 10 | 12 | 15 | 40 | 60 | 60 | 60 | 60 | 50 | 50 | 50 | 50 | 1.5 | ||
PEEP, cmH20 | 10 | 14 | 14 | 12 | 12 | 10 | ||||||||||
Peak AP, cmH20 | 16 | 35 | 34 | 38 | 37 | 35 | ||||||||||
VT, mL | 450 | 325 | 441 | 437 | 438 | |||||||||||
Compliance, mL/cmH20* | 21.4 | 16.3 | 17.0 | 17.5 | 17.5 | |||||||||||
pH | 7.46 | 7.45 | 7.46 | 7.49 | 7.45 | 7.28 | 7.24 | 7.37 | 7.491 | 7.51 | 7.5 | 7.49 | ||||
PaCO2, mm Hg | 35 | 37 | 35 | 31 | 35 | 49 | 66 | 51 | 39.8 | 37 | 41 | 36 | ||||
BE, mmol/L | 1.1 | 1.3 | 1.2 | 0.6 | 0.2 | −4.2 | −1.2 | 2.6 | 6 | 5.6 | 7.6 | 3.6 | ||||
PaO2, mm Hg | 52 | 57 | 62 | 43 | 67 | 71 | 97 | 71 | 57.6 | 68 | 78 | 66 | ||||
PaO2/FiO2 | 51 | 67 | 71 | 162 | 142 | 115 | 171 | 155 |
Timeline correlating arterial blood gases and respiratory support with select investigations and treatment. Although SpO2 intermittently fell below 80%, each incident triggered an assessment by a physician and a series of interventions. So, the arterial blood gas analyses presented reflect the patient’s oxygenation after adjustment of respiratory support. For example, on day 9, oxygenation did not improve significantly after endotracheal ventilation and initiation of mechanical ventilation so the patient was positioned prone. The arterial blood gas analyses, performed at 04:40 on day 10 and 03:40 on day 12, reflect the improvement in oxygenation after several hours of prone positioning and reduction of PEEP.
*Dynamic compliance was calculated.
VC AC, volume control-assist control; Peak AP, peak airway pressure; BE, base excess; BiPAP, bilevel positive airway pressure; CRP, C reactive protein; ETT, endotracheal tube; FiO2, fractional inspired oxygen; FM, face mask; HFNC, high-flow nasal cannula; LDH, lactate dehydrogenase; NC, nasal cannula; NRB, non-rebreathe; PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; PEEP, positive end expiratory pressure; PFO, patent foramen ovale; RR, respiratory rate; RTLIAS, right-to-left interatrial shunt; SpO2, oxygen saturation; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; VC+, volume control plus; VT, tidal volume.